Clene Inc

Clene Inc. Insider Surge: CEO‑Level Executives and Board Members Load Up on Near‑Market Options, Signaling Confidence Amid Volatile Valuation

Clene Inc. insider option grants signal confidence amid volatility—explore why executives bet on a $4.73 strike and what it means for investors.

DirectorDealingsBot

20/02/2026, 22:24

2 minutes to read

Clene Inc. Owner Ugwumba Chidozie Continues Steady Insider Sell‑off Amid Uncertain Biotech Outlook

Clene insider sales reveal cautious strategy: owner sells 3% monthly, hinting at volatility; investors advised to buy on dips and watch for new breakthroughs.

DirectorDealingsBot

22/01/2026, 00:29

3 minutes to read

Clene Inc. Insider Mosca Unloads 57,000 Shares, Buys Big Warrant Batch as FDA Milestone Looms

Clene Inc.’s insider sale‑buy strategy shows Mosca’s liquidity shift while holding future upside—insider confidence, FDA milestones, and warrant pricing unveiled.

DirectorDealingsBot

14/01/2026, 01:02

3 minutes to read

Clene Insider: Director Mattin David J. Buys 33K Shares + 133K Warrant Units Ahead of FDA Meeting, Betting on CNM‑Au8 Breakthrough.

Insider David Matlin’s big Clene Inc. buy and warrants show confidence in the CNM‑Au8 biomarker’s FDA prospects, offering investors a chance to profit if regulatory milestones spark a rally.

DirectorDealingsBot

13/01/2026, 22:30

3 minutes to read

Clene Inc. Insider Matlin Buys 33,333 Shares and $133,333 in Warrants Amid FDA‑Driven Bullish Bet

Insider buy of Clene Inc. shares and performance‑triggered warrants shows confidence in upcoming FDA review of CNM‑Au8; investors weigh potential upside versus risk.

DirectorDealingsBot

13/01/2026, 21:04

3 minutes to read

Clene Inc. Insider Chidozie Dumps Nearly 6,000 Shares in Mid‑January, Raising Red‑Flag Signals for Investors

Clene Inc.’s insider sales trend shows owner Ugwumba Chidozie’s steady selling amid weak short‑term prospects, signaling caution for investors.

DirectorDealingsBot

07/01/2026, 23:43

2 minutes to read